



165 – 10551 Shellbridge Way
Richmond, BC, V6X 2W8

BioMark Diagnostics Inc. Amends and Re-files Management Discussion & Analysis

Vancouver, B.C., December 2, 2015– BioMark Diagnostics Inc. (“BioMark”, “the Company”) – As a result of a review by the British Columbia Securities Commission, we are issuing the following press release to clarify our disclosure.

Amended and Restated Management Discussion and Analysis (MD&A)

The Company has amended and restated its MD&As for the interim periods ending September 30, 2015 to correct the references to the quarterly results in the MD&As to comply with part 4.8 of National Instrument 51-102 Continuous Disclosure Obligations (“NI 51-102”).

The amended and restated MD&As have been posted to SEDAR (www.sedar.com) under the Company’s SEDAR profile

About BioMark Diagnostics Inc.

BioMark Diagnostics is developing proprietary, non-invasive, and accurate cancer diagnostic solutions, which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors.

Further information about BioMark Diagnostics is available under its profile on the SEDAR website www.sedar.com and on the CSE website www.thecse.ca.

Company Contact

Rashid Ahmed Bux
President & CEO
BioMark Diagnostics Inc.
604-282-6567
info@biomarkdiagnostics.com

Forward-Looking Information

This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information,

whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The CSE has not reviewed, approved or disapproved the content of this press release.